Effect of Age on Efficacy and Safety of Fluticasone Furoate/Vilanterol (FF/VI), Umeclidinium (UMEC), and UMEC + FF/VI in Patients with Chronic Obstructive Pulmonary Disease: Analyses of Five Randomized Clinical Trials

References

• Buist AS, McBurnie MA, Vollmer WM, et al. International variation in the prevalence of COPD (The BOLD Study): a population-based prevalence study. Lancet. 2007;370(9589):741–750. doi:10.1016/S0140-6736(07)61377-4
   PubMed Web of Science ®Google Scholar
• Sullivan J, Pravosud V, Mannino DM, Siegel K, Choate R, Sullivan T. National and state estimates of COPD morbidity and mortality — United States, 2014–2015. Chronic Obstr Pulm Dis. 2018;5(4):324–333. doi:10.15326/jcopdf.5.4.2018.0157
   PubMed Web of Science ®Google Scholar
• Fried TR, Vaz Fragoso CA, Rabow MW. Caring for the older person with chronic obstructive pulmonary disease. JAMA. 2012;308(12):1254–1263. doi:10.1001/jama.2012.12422
   PubMed Web of Science ®Google Scholar
• Mangoni AA, Jackson SHD. Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications. Br J Clin Pharmacol. 2004;57(1):6–14. doi:10.1046/j.1365-2125.2003.02007.x
   PubMed Web of Science ®Google Scholar
• Hanania NA, Sharma G, Sharafkhaneh A. COPD in the elderly patient. Semin Respir Crit Care Med. 2010;31(05):596–606. doi:10.1055/s-0030-1265900
   PubMedGoogle Scholar
• Taffet GE, Donohue JF, Altman PR. Considerations for managing chronic obstructive pulmonary disease in the elderly. Clin Interv Aging. 2014;9:23–30. doi:10.2147/CIA.S52999
   PubMed Web of Science ®Google Scholar
• Turan O, Turan PA, Mirici A. Parameters affecting inhalation therapy adherence in elderly patients with chronic obstructive lung disease and asthma. Geriatr Gerontol Int. 2017;17(6):999–1005. doi:10.1111/ggi.12823
   PubMed Web of Science ®Google Scholar
• Jarvis S, Ind PW, Shiner RJ. Inhaled therapy in elderly COPD patients; time for re-evaluation? Age Ageing. 2007;36(2):213–218. doi:10.1093/ageing/afl174
   PubMed Web of Science ®Google Scholar
• Bourgeois FT, Olson KL, Tse T, Ioannidis JP, Mandl KD. Prevalence and characteristics of Interventional Trials conducted exclusively in elderly persons: a cross-sectional analysis of Registered Clinical Trials. PLoS One. 2016;11(5):e0155948. doi:10.1371/journal.pone.0155948
   PubMed Web of Science ®Google Scholar
• Anathhanam S, Powis RA, Cracknell AL, Robson J. Impact of prescribed medications on patient safety in older people. Ther Adv Drug Saf. 2012;3(4):165–174. doi:10.1177/2042098612443848
   PubMedGoogle Scholar
• Ray R, Tombs L, Asmus MJ, et al. Efficacy of Umeclidinium/Vilanterol in elderly patients with COPD: a pooled analysis of Randomized Controlled Trials. Drugs Aging. 2018;35(7):637–647. doi:10.1007/s40266-018-0558-y
   PubMed Web of Science ®Google Scholar
• Sutton L, Baylis LE, Jain R, Collison K, Mannino D, Patel P. Ease and correct use of ELLIPTA by age in patients with asthma and COPD. Chest. 2018;154(4):745A–746A. doi:10.1016/j.chest.2018.08.673
   Web of Science ®Google Scholar
• Kerwin EM, Scott-Wilson C, Sanford L, et al. A randomised trial of fluticasone furoate/vilanterol (50/25 μg; 100/25 μg) on lung function in COPD. Respir Med. 2013;107(4):560–569. doi:10.1016/j.rmed.2012.12.014
   PubMed Web of Science ®Google Scholar
• Kerwin EM, Scott-Wilson C, Sanford L, et al. Corrigendum to “A randomised trial of fluticasone furoate/vilanterol (50/25 μg; 100/25 μg) on lung function in COPD” [Respir Med, 107 (2013) 560–569]. Respir Med. 2013;107(12):2094. doi:10.1016/j.rmed.2013.10.008
   Web of Science ®Google Scholar
• Martinez FJ, Boscia J, Feldman G, et al. Fluticasone furoate/vilanterol (100/25; 200/25 μg) improves lung function in COPD: a randomised trial. Respir Med. 2013;107(4):550–559. doi:10.1016/j.rmed.2012.12.016
   PubMed Web of Science ®Google Scholar
• Martinez FJ, Boscia J, Feldman G, et al. Corrigendum to “Fluticasone furoate/vilanterol (100/25; 200/25 μg) improves lung function in COPD: a randomised trial” [Respir Med 107 (2013) 550–559]. Respir Med. 2013;107(12):2092–2093. doi:10.1016/j.rmed.2013.10.009
   Web of Science ®Google Scholar
• Donohue JF, Maleki-Yazdi MR, Kilbride S, Mehta R, Kalberg C, Church A. Efficacy and safety of once-daily umeclidinium/vilanterol 62. 5/25mcg in COPD. Respir Med. 2013;107(10):1538–1546. doi:10.1016/j.rmed.2013.06.001
   PubMed Web of Science ®Google Scholar
• Siler TM, Kerwin E, Sousa AR, Donald A, Ali R, Church A. Efficacy and safety of umeclidinium added to fluticasone furoate/vilanterol in chronic obstructive pulmonary disease: results of two randomized studies. Respir Med. 2015;109(9):1155–1163. doi:10.1016/j.rmed.2015.06.006
   PubMed Web of Science ®Google Scholar
• Kerstjens HA, Rijcken B, Schouten JP, Postma DS. Decline of FEV1 by age and smoking status: facts, figures, and fallacies. Thorax. 1997;52(9):820–827. doi:10.1136/thx.52.9.820
   PubMed Web of Science ®Google Scholar
• Kohansal R, Martinez-Camblor P, Agustí A, Buist AS, Mannino DM, Soriano JB. The natural history of chronic airflow obstruction revisited: an analysis of the Framingham offspring cohort. Am J Respir Crit Care Med. 2009;180(1):3–10. doi:10.1164/rccm.200901-0047OC
   PubMed Web of Science ®Google Scholar
• Grant AC, Walker R, Hamilton M, Garrill K. The ELLIPTA® dry powder inhaler: design, functionality, in vitro dosing performance and critical task compliance by patients and caregivers. J Aerosol Med Pulm Drug Deliv. 2015;28(6):474–485. doi:10.1089/jamp.2015.1223
   PubMed Web of Science ®Google Scholar
• Hamilton M, Leggett R, Pang C, Charles S, Gillett B, Prime D. In vitro dosing performance of the ELLIPTA® Dry powder inhaler using asthma and COPD patient inhalation profiles replicated with the electronic lung (eLung™). J Aerosol Med Pulm Drug Deliv. 2015;28(6):498–506. doi:10.1089/jamp.2015.1225
   PubMed Web of Science ®Google Scholar
• Prime D, de Backer W, Hamilton M, et al. Effect of disease severity in asthma and chronic obstructive pulmonary disease on inhaler-specific inhalation profiles through the ELLIPTA® dry powder inhaler. J Aerosol Med Pulm Drug Deliv. 2015;28(6):486–497. doi:10.1089/jamp.2015.1224
   PubMed Web of Science ®Google Scholar
• Altman P, Wehbe L, Dederichs J, et al. Comparison of peak inspiratory flow rate via the Breezhaler®, Ellipta® and HandiHaler® dry powder inhalers in patients with moderate to very severe COPD: a randomized cross-over trial. BMC Pulm Med. 2018;18(1):100. doi:10.1186/s12890-018-0662-0
   PubMed Web of Science ®Google Scholar
• Hanania NA, Mannino DM, Criner GJ, et al. Effect of age on the efficacy and safety of once-daily single-inhaler triple therapy fluticasone Furoate/Umeclidinium/Vilanterol in patients with chronic obstructive pulmonary disease: a post hoc analysis of the IMPACT Trial. Chest. 2021;159:985–995. doi:10.1016/j.chest.2020.09.253
   PubMed Web of Science ®Google Scholar
• Montuschi P, Malerba M, Santini G, Miravitlles M. Pharmacological treatment of chronic obstructive pulmonary disease: from evidence-based medicine to phenotyping. Drug Discov Today. 2014;19(12):1928–1935. doi:10.1016/j.drudis.2014.08.004
   PubMed Web of Science ®Google Scholar